Superworth

Pro DEX revenue PDEX

Sales by quarter and over the last twelve months, from 2010.

Last 12 months, to Sep 30, 2026
$79.6M
Latest quarter, Q1 FY27
$20.6M
+11% on a year earlier
Fiscal year 2026
$77.5M
+16% on the year before

Pro DEX's revenue was $79.6M over the twelve months to Sep 30, 2026, up 13% on a year earlier.

In its latest quarter, Q1 FY27, it was $20.6M, up 11% on the same quarter a year before.

Over the five fiscal years to FY2026 it grew 15% a year on average.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2026$77.5M+16%
FY2025$66.6M+24%
FY2024$53.8M+17%
FY2023$46.1M+10%
FY2022$42M+11%
FY2021$38M+9%
FY2020$34.8M+28%
FY2019$27.2M+21%
FY2018$22.5M+2%
FY2017$21.9M+13%
FY2016$19.5M+46%
FY2015$13.4M+24%
FY2014$10.8M−12%
FY2013$12.3M−29%
FY2012$17.3M−33%

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q1 FY27$20.6M+11%$79.6M
Q4 FY26$20.4M+17%$77.5M
Q3 FY26$19.9M+15%$74.6M
Q2 FY26$18.7M+11%$72.1M
Q1 FY26$18.5M+24%$70.2M
Q4 FY25$17.5M+16%$66.6M
Q3 FY25$17.4M+22%$64.1M
Q2 FY25$16.8M+33%$61M
Q1 FY25$14.9M+25%$56.8M
Q4 FY24$15M+41%$53.8M
Q3 FY24$14.3M+9%$49.5M
Q2 FY24$12.6M+12%$48.2M

Against its peers

Companies in Medical - Instruments & Supplies nearest Pro DEX's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
PDEXPro DEX$79.6M+13% a year
UTMDUtah Medical Products$36.1M−7% a year
INFUInfuSystem$143.3M+2% a year
EMBCEmbecta$1B−8% a year
KEQUKewaunee Scientific$277.2M+5% a year
TCMDTactile Systems Technology$350.3M+17% a year
APTAlpha Pro Tech$61.9M+6% a year
MOVMovado$689.9M+5% a year
NEPHNephros$20.7M+24% a year
IRMDIradimed$89.3M+11% a year
IARTIntegra Lifesciences$1.7B+1% a year
Peer median$210.3M

Where Pro DEX ranks

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Pro DEX

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.